Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $47.50, but opened at $51.80. Zealand Pharma A/S shares last traded at $51.80, with a volume of 130 shares.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of several analyst reports. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Zealand Pharma A/S presently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The business has a fifty day moving average of $45.44 and a two-hundred day moving average of $49.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of 3.84 and a beta of 0.88.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.